Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia

Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia

MDM2 is frequently overexpressed in acute myeloid leukaemia leading to p53 inactivation. Here, the authors are demonstrating that an inhibitor of p53-MDM2 interaction, DS-5272, induce in vivo tumour regression through immune response regulation.

Bibliographic Details
Main Authors: Yasutaka Hayashi, Susumu Goyama, XiaoXiao Liu, Moe Tamura, Shuhei Asada, Yosuke Tanaka, Tomofusa Fukuyama, Mark Wunderlich, Eric O’Brien, Benjamin Mizukawa, Satoshi Yamazaki, Akiko Matsumoto, Satoshi Yamasaki, Tatsuhiro Shibata, Koichi Matsuda, Goro Sashida, Hitoshi Takizawa, Toshio Kitamura
Format: Article
Language:English
Published: Nature Publishing Group 2019-10-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-019-12555-1

Internet

https://doi.org/10.1038/s41467-019-12555-1

Similar Items